Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$5.9MCash on Hand
8.8mo Cash Runway
Follow ONCO by emailGet an email when ONCO reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about ONCO, unsubscribe in one click. Privacy
📄 Latest SEC Filings in Plain English
Nov 16, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Nov 12, 2026 ·
Shareholder vote Onconetix stockholders elected Josh Epstein as a Class II director and approved issuing up to 154,856,150 common shares on conversion of Series F Preferred Stock from a July 29, 2026 private placement. Holders also approved a reverse split of 1-for-2 to 1-for-15, to be completed within one year. Form 8-K · SEC filing
Nov 9, 2026 ·
Restructuring Onconetix effected a 1-for-10 reverse stock split, effective 12:01 a.m. ET on November 6, 2026. Outstanding common shares fell from about 6.7 million to about 670,000, and the stock trades as ONCO under a new CUSIP. Form 8-K · SEC filing
Nov 6, 2026 ·
Deal Onconetix signed a First Amendment to its Share Exchange Agreement with Realbotix. If Net Cash is under $12.5 million and closing proceeds, the Seller will own 95% of Fully Diluted Shares. Net Cash now includes the Grid Promissory Note balance, and the End Date is extended to March 31, 2027. Form 8-K · SEC filing
Oct 26, 2026 ·
Listing Onconetix announced a one-for-ten reverse stock split of its common stock, effective 12:01 a.m. ET on November 6, 2026, with a new CUSIP 68237Q500. Together with the May 21, 2026 split, the aggregate ratio is one-for-one hundred. Shares outstanding are expected to fall from about 5.9 million to about 589,000. Form 8-K · SEC filing · Press release
Oct 23, 2026 ·
Financing Onconetix made an additional $500,000 advance to Realbotix, LLC on October 22, 2026, under the Grid Promissory Note dated September 11, 2026. Aggregate principal outstanding under the Note is now $3.0 million, and the Note's terms are unchanged. Form 8-K · SEC filing
Sep 14, 2026 ·
Financing Onconetix entered a Grid Promissory Note with Realbotix, LLC for up to $5.0 million in loans, with $2.5 million advanced on September 11, 2026. Form 8-K · SEC filing · Press release
Sep 8, 2026 ·
Financing Onconetix is registering up to 100,000,000 shares of common stock for resale by a selling stockholder, shares issuable on conversion of Series F preferred stock bought in a July 2026 private placement at an initial conversion price of $0.9767. The company receives no proceeds from these resales. Form 424B3 · SEC filing
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
💰 Cash Runway & Dilution Risk
ONCO holds $5.9M in cash and short-term investments (as of Jun 30, 2026) and burns about $2M/quarter from operations,
an estimated runway of 8.8 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:45 · Elevated
Cash runway 9 months +30
Going-concern doubt in the latest 10-Q +15These factors raise substantial doubt about the Company’s ability to continue as a going concern within one year from the date of the issuance of these consolidated financial statements.10-Q, Nov 2026
Share count 820,611 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full ONCO picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ONCO and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.